Stockscreener 앱 받기
3.80
1.60%
0.06
전일 마감가:
$3.74
열려 있는:
$3.8
하루 거래량:
45,357
Relative Volume:
0.67
시가총액:
$164.05M
수익:
-
순이익/손실:
$-103.21M
주가수익비율:
-0.8261
EPS:
-4.6001
순현금흐름:
$-26.70M
1주 성능:
+5.85%
1개월 성능:
-9.52%
6개월 성능:
-52.38%
1년 성능:
-57.73%
1일 변동 폭
$3.68
$3.98
1주일 범위
$3.49
$3.98
52주 변동 폭
$2.65
$11.00
Engene Holdings Inc Stock (ENGN) Company Profile
명칭
Engene Holdings Inc
전화
(514) 332-4888
주소
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
ENGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
3.80 | 164.05M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 개시 | Piper Sandler | Overweight |
| 2025-02-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-23 | 개시 | H.C. Wainwright | Buy |
| 2024-11-27 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2024-04-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-03-28 | 개시 | UBS | Buy |
| 2024-03-08 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | Leerink Partners | Outperform |
모두보기
Engene Holdings Inc 주식(ENGN)의 최신 뉴스
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade) (NASDAQ:ENGN) - Seeking Alpha
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) to four newly-hired employees - BioSpace
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
JMP reiterates market outperform rating on enGene stock on clinical progress By Investing.com - Investing.com Nigeria
JMP reiterates market outperform rating on enGene stock on clinical progress - Investing.com Australia
Engene stock maintains buy rating at H.C. Wainwright on LEGEND trial - Investing.com
enGene Holdings Inc. adopts new employee stock plan By Investing.com - Investing.com Nigeria
enGene Holdings Reports Q2 2025 Financial Results - TipRanks
Engene stock maintains Outperform rating at Raymond James on strong execution By Investing.com - Investing.com South Africa
Engene stock maintains Outperform rating at Raymond James on strong execution - Investing.com India
EnGene Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2025 - MarketScreener
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
enGene Holdings Inc reports results for the quarter ended April 30Earnings Summary - TradingView
EnGene Reports Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
enGene Holdings Inc. SEC 10-Q Report - TradingView
enGene Holdings CMO Resignation Announced - MSN
enGene Holdings Approves 2025 Employee Stock Purchase Plan - TipRanks
enGene Holdings Inc. adopts new employee stock plan - Investing.com
ENGENE HOLDINGS Earnings Preview: Recent $ENGN Insider Trading, Hedge Fund Activity, and More - Nasdaq
enGene Holdings Expands with New Boston Lease - TipRanks
(ENGN) On The My Stocks Page - news.stocktradersdaily.com
enGene CMO Dr. Raj Pruthi to step down mid-June By Investing.com - Investing.com India
EnGene Chief Medical Officer Raj Pruthi to Step Down - marketscreener.com
enGene CMO Dr. Raj Pruthi Resigns - citybiz
enGene (ENGN) CMO Raj Pruthi Steps Down | ENGN Stock News - GuruFocus
enGene CMO Dr. Raj Pruthi to step down mid-June - Investing.com
enGene Announces the Resignation of its Chief Medical Officer - Business Wire
enGene to Present at the Jefferies Global Healthcare Conference - BioSpace
enGene appoints new Chief Global Commercialization Officer By Investing.com - Investing.com South Africa
enGene Names Amy Pott as Chief Global Commercialization Officer - citybiz
enGene appoints new Chief Global Commercialization Officer - Investing.com Australia
enGene (ENGN) Appoints Amy Pott as New Chief Global Commercialization Officer | ENGN Stock News - GuruFocus
EnGene Names Amy Pott As Chief Global Commercialization Officer - marketscreener.com
When (ENGN) Moves Investors should Listen - news.stocktradersdaily.com
Head-To-Head Review: enGene (NASDAQ:ENGN) vs. ImmunityBio (NASDAQ:IBRX) - Defense World
Where are the Opportunities in (ENGN) - news.stocktradersdaily.com
Is enGene Holdings (NASDAQ:ENGN) Using Too Much Debt? - simplywall.st
(ENGN) Trading Signals - news.stocktradersdaily.com
Citizens JMP reiterates Engene stock with $18 target By Investing.com - Investing.com Nigeria
Citizens JMP reiterates Engene stock with $18 target - Investing.com
enGene to Participate in Upcoming Investor Conferences - Yahoo Finance
enGene to Participate in Upcoming May 2025 Investor Conferences - BioSpace
enGene Holdings Inc.'s (NASDAQ:ENGN) largest shareholders are private equity firms with 38% ownership, institutions own 35% - Yahoo Finance
Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
(ENGN) Technical Data - news.stocktradersdaily.com
enGene (NASDAQ:ENGN) & Innate Pharma (OTCMKTS:IPHYF) Head-To-Head Survey - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts - Defense World
Trend Tracker for (ENGN) - news.stocktradersdaily.com
Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
enGene Expands Team with New Hires, Grants 144,650 Shares in Stock Options - Stock Titan
Engene Holdings Inc (ENGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Engene Holdings Inc 주식 (ENGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 08 '24 |
Buy |
6.60 |
800 |
5,278 |
2,470,633 |
| Cooper Ronald Harold Wilfred | Chief Executive Officer |
Sep 27 '24 |
Buy |
5.70 |
10,000 |
57,000 |
10,000 |
0.68%
0.50%
자본화:
|
볼륨(24시간):